Pfizer Unit Hit With Another Suit Over Tossed Lyrica Patent

Law360, London (November 12, 2020, 5:54 PM GMT) -- Ranbaxy has sued Pfizer-owned Warner-Lambert for lost profits, becoming the latest generic-drug maker to seek damages from the years it couldn't launch a version of the blockbuster drug Lyrica because of a patent that the U.K. Supreme Court later invalidated.

Ranbaxy (UK) Ltd., a subsidiary of Indian pharmaceutical company Sun Pharma, said in its newly public Oct. 26 High Court claim that it had obtained marketing authority for the sale of generic pregabalin and was due to launch in the U.K. in January 2016, but didn't due to Warner-Lambert's claims it still had patent protection for the drug under its secondary...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!